Walleye Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Walleye Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,200	Closed	-$1.14M	–	5502
2023 Q2	$1.14M	Buy	11,200 +8,400	+300%	+$795K	﹤0.01%	1746
2023 Q1	$255K	Buy	+2,800	New	+$164K	﹤0.01%	2257
2022 Q4	–	Sell	-18,500	Closed	-$465K	–	3788
2022 Q3	$465K	Buy	+18,500	New	+$513K	0.01%	1531

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's RETA Position: Q3 2023 in Review

Walleye Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,923 shares — an estimated $196K sold.

Walleye Capital first reported a position in RETA in Q3 2019 and held it in 5 quarters. The position peaked at $1.35M in Q4 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Walleye Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 1,923 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $196K.
Walleye Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 5 quarters.
Walleye Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.35M in Q4 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.